The data will be presented during the International Liver Congress™ 2019, the Annual Meeting of the European Association for the Study of the Liver (EASL).
The five-day congress begins on April 10. Dr Kevin Klucher will present on April 12, from 9am to 5pm (Central European Summer Time).
TERN-101 reduces liver steatosis, inflammation, ballooning and fibrosis in a preclinical model of non-alcoholic steatohepatitis (NASH).
On the other hand, TERN-201 reduces non-alcoholic fatty liver disease activity score and fibrosis in preclinical models of NASH.
“We believe TERN-101 and TERN-201 have the potential to be meaningful new treatments for NASH, a condition with no existing treatment options, and the data we are presenting at EASL reinforces our confidence,” said Terns chief medical officer, Erin Quirk.
She added that both of the company’s lead programmes remained on track to generate clinical data in 2019, and they looked forward to continuing their work towards developing effective and safe combination therapies for patients with NASH and liver fibrosis.
Terns Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, focused on the discovery and development of medicines for chronic liver disease and cancer.
Based in China and the United States, the company is advancing a pipeline of small molecule drug candidates for the treatment of NASH and cancer, across multiple modalities.
-- BERNAMA
No comments:
Post a Comment